Filter by Year:

Immuron (ASX:IMC) reveals positive anti-diarrhoea vaccine results

9 November 2020

Immuron (IMC) is surging on the ASX today after revealing some encouraging progress in the development of a treatment for diarrhoea.

Immuron (ASX:IMC) takes steps towards FDA approval for stomach bug treatment

12 October 2020

Biopharma company Immuron (IMC) is set to start clinical trials of its candidate drug, IMM124E, in collaboration with the U.S.-based Uniformed Services University.

Immuron’s commercially available products found to neutralise COVID-19 during in vitro research

21 July 2020

Biopharmaceutical company Immuron (ASX: IMC) has revealed the IMM-124E, which is used in its commercially available Travelan product, has demonstrated neutralising activity against COVID-19.

Immuron (ASX:IMC) develops research agreement

22 June 2020

Biopharmaceutical company Immuron (IMC) has executed its previously announced research agreement involving the US Naval Medical Research Centre and the CSIRO.

Immuron and US Naval Medical Research Center prepare to develop novel oral therapeutic for E-Coli

10 June 2020

Dual-listed biopharmaceutical company Immuron (ASX: IMC) is on course to make progress with a new oral therapeutic to treat campylobacteriosis and E. coli infections after development partner Naval Medical Research Center (NMRC) requested a pre-IND....